CRIS Current Research Information System

VENTURI, CLAUDIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.517
AS - Asia 3.015
EU - Europa 2.489
AF - Africa 198
SA - Sud America 193
Continente sconosciuto - Info sul continente non disponibili 189
OC - Oceania 4
Totale 9.605
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.451
VN - Vietnam 824
SG - Singapore 789
CN - Cina 732
GB - Regno Unito 630
IT - Italia 435
SE - Svezia 334
DE - Germania 318
HK - Hong Kong 208
FR - Francia 159
IN - India 140
BR - Brasile 133
RU - Federazione Russa 126
NL - Olanda 113
IE - Irlanda 83
ZA - Sudafrica 67
JP - Giappone 65
TG - Togo 58
EE - Estonia 50
CH - Svizzera 47
FI - Finlandia 44
UA - Ucraina 42
KR - Corea 38
JO - Giordania 35
CA - Canada 34
BG - Bulgaria 31
BD - Bangladesh 30
NG - Nigeria 30
PH - Filippine 27
AR - Argentina 25
CI - Costa d'Avorio 22
IR - Iran 20
IQ - Iraq 19
TH - Thailandia 19
BE - Belgio 17
MX - Messico 13
PL - Polonia 13
AT - Austria 10
TW - Taiwan 10
EC - Ecuador 9
TR - Turchia 9
LB - Libano 8
ES - Italia 7
GR - Grecia 7
SC - Seychelles 7
VE - Venezuela 7
ID - Indonesia 6
JM - Giamaica 6
UZ - Uzbekistan 6
CL - Cile 5
PE - Perù 5
PK - Pakistan 5
SA - Arabia Saudita 5
TN - Tunisia 5
AU - Australia 4
CR - Costa Rica 4
MY - Malesia 4
PT - Portogallo 4
PY - Paraguay 4
QA - Qatar 4
RO - Romania 4
AE - Emirati Arabi Uniti 3
DK - Danimarca 3
LT - Lituania 3
MA - Marocco 3
BO - Bolivia 2
CO - Colombia 2
CZ - Repubblica Ceca 2
EU - Europa 2
GT - Guatemala 2
KH - Cambogia 2
KZ - Kazakistan 2
LV - Lettonia 2
NI - Nicaragua 2
OM - Oman 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BZ - Belize 1
CY - Cipro 1
EG - Egitto 1
ET - Etiopia 1
HN - Honduras 1
IL - Israele 1
KE - Kenya 1
LY - Libia 1
MD - Moldavia 1
MK - Macedonia 1
MT - Malta 1
RS - Serbia 1
SN - Senegal 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
ZW - Zimbabwe 1
Totale 9.420
Salva come PNG Salva come JPEG
Città #
Southend 587
Singapore 531
Ashburn 404
Chandler 357
Fairfield 258
San Jose 219
Hong Kong 196
Ho Chi Minh City 173
Beijing 161
Houston 158
Seattle 139
Woodbridge 139
Wilmington 134
Hanoi 133
Dong Ket 117
Princeton 114
Ann Arbor 110
Santa Clara 87
Cambridge 86
Bologna 84
Dublin 83
Boardman 79
New York 67
Lomé 58
Lauterbourg 55
Nanjing 55
Tokyo 53
Westminster 53
Padova 50
Los Angeles 47
Hefei 45
Bern 42
Medford 42
Amman 35
Frankfurt am Main 34
Helsinki 30
Milan 30
Sofia 30
Munich 29
Abeokuta 27
Redmond 27
Bremen 26
Seoul 26
Buffalo 25
Hebei 25
São Paulo 25
Shenyang 24
Jinan 23
Abidjan 22
Haiphong 22
Saint Petersburg 22
Berlin 21
Da Nang 21
Redondo Beach 21
San Diego 19
Jiaxing 18
Brussels 17
Council Bluffs 16
Dallas 16
Falls Church 16
Johannesburg 16
Nanchang 15
Redwood City 15
Changsha 14
Guangzhou 14
Orem 14
Rome 14
Shanghai 14
Tianjin 14
Turin 14
Chicago 13
Nuremberg 13
Baghdad 12
Tehran 11
Atlanta 10
Florence 10
Mountain View 10
Turku 10
Zhengzhou 10
Falkenstein 9
Norwalk 9
Paris 9
Phoenix 9
Montreal 8
Toronto 8
Bangkok 7
Dearborn 7
Hải Dương 7
Ningbo 7
Warsaw 7
Amsterdam 6
Bengaluru 6
Brescia 6
Bến Tre 6
Can Tho 6
Chengdu 6
Denver 6
Fuzhou 6
Hangzhou 6
London 6
Totale 5.953
Salva come PNG Salva come JPEG
Nome #
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 291
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis 249
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 235
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 230
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 223
Inhibition of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) is a novel therapeutic strategy in B- and T-Acute Lymphoblastic Leukemia (ALL). 217
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 215
Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia 215
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report 214
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 195
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 190
Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients 186
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 186
Backtracking BCR-ABL1 Mutants in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Relapsing on Tyrosine Kinase Inhibitors with Deep Sequencing: Implications for Routine Mutation Testing 185
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 184
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 180
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 180
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 176
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 175
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 174
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL) 168
Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets 167
An Italian Multicentre Study Using Different Digital PCR Instruments on BCR-ABL1 Positive Patients at Different Levels of CML Disease 167
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia 164
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 163
Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome 163
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 162
Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response 160
Evaluation of the Diasorin Q-Lamp technology for the molecular diagnosis of the philadelphia positive leukemias: an italian multicenter study 160
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 160
Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome 160
COMPLEX GENETIC HETEROGENEITY INFLUENCES PROGNOSIS IN ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA NEGATIVE FOR RECURRENT FUSION GENES 159
Tp53 mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome 159
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse. 157
One-Step Quantitative Molecular Approach for Detection of BCR/ABL1 Rearrangement and for Monitoring of Minimal Residual Disease in CML Patients: An Inter Laboratory Study 155
Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy 153
Evaluation of Cepheid Xpert® BCR-ABL Monitor Assay in Three Italian Reference Centers for Monitoring of BCR-ABL Transcript Levels in CML Patients 151
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 149
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights 146
Emergence and Cytogenetic Clonal Evolution of Chromosome 7 Abnormalities in Myeloid Malignancies: Investigating the Role of Telomere Dysfunction 144
SEVERAL FUSION TRANSCRIPTS ARE DETECTED BY NEXT GENERATION PAIRED END TRANSCRIPTOMIC RE-SEQUENCING APPROACH IN ADULT BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 144
Recurrent gastrointestinal hemorrhage in treatment with dasatinib in a patient showing SMAD4 mutation with acute lymphoblastic leukemia Philadelphia positive and juvenile polyposis hereditary hemorrhagic telangiectasia syndrome 144
Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience 143
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse 142
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 142
Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy 141
Bcr-Abl kinase domain mutations and resistance in Ph+ acute lymphoblastic leukemia from the imatinib to the 2nd-generation TKI era 140
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. 139
Loss of Heterozygosity At the C Wild-Type Allele of rs1042522 in the TP53 Gene Frequently Occurs During Progression of Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) 137
Pharmacological interaction and side effects in oncohaematology: a retrospective observational study 130
Molecular characterization of TP53 mutations in B-acute lymphoblastic leukemia (B-ALL) reveals missense substitutions, aberrant exon-junctions and intron retention events 126
Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain Allows Earlier Detection and More Accurate Characterization of Resistant Subclones in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Receiving Tyrosine Kinase Inhibitor-Based Therapies 126
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia 123
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 122
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 120
SET-UP OF A MULTIPLEX PCR TO RAPIDLY DETECT IKZF1 (IKAROS) GENE BREAKPOINT DELETION IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 120
Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement 112
null 76
Dynamics of IDH1/2 mutated clones in acute myeloid leukemia challenge their use as universal MRD markers 11
Totale 9.605
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.938
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.938
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022970 0 18 56 83 122 70 11 48 56 88 193 225
2022/20231.291 152 196 48 177 106 111 33 80 205 26 85 72
2023/2024344 11 58 21 36 21 88 14 29 23 15 10 18
2024/20251.213 48 181 122 104 121 44 100 30 22 149 53 239
2025/20262.866 239 188 219 153 343 135 261 107 795 246 94 86
2026/2027141 85 56 0 0 0 0 0 0 0 0 0 0
Totale 9.605